In this study, cytokine release by tumor-draining lymph node cells sensitized in vitro (IVS-TDLN) was examined and correlated with therapeutic efficacy in adoptive immunotherapy. Mice bearing immunologically distinct MCA 207 and MCA 205 sarcoma tumors were utilized in criss-cross experiments. IVS-TDLN obtained from mice bearing 10-day subcutaneous (s.c.) rumors mediated immunologically specific regression of established 3-day pulmonary metastases, but demonstrated non-specific cytolytic reactivity against both tumors in a 4-h 5~Cr-release assay. By contrast, these IVS-TDLN cells were found specifically to secrete granulocyte/macrophage colonystimulating factor (GM-CSF) and interferon Y (IFNy) when restimulated in vitro with irradiated tumor cells. To determine the predictive value of tumor-specific cytokine release with in vivo therapeutic efficacy, a kinetic analysis of antitumor activities of TDLN obtained from animals bearing MCA 207 tumors for increasing lengths of time was performed. IVS-TDLN cells from mice bearing day-7, -10 and -14 s.c. rumors manifested rumor-specific release of GM-CSF and IFNy, and mediated significant antimmor reactivity in vivo. In contrast IVS-LN cells from day-0 and day-21 tumor-bearing animals did not release significant amounts of GM-CSF and IFNy, and were not therapeutically efficacious in vivo. Day-4 IVS-TDLN released high levels of GM-CSF and IFN 7 non-specifically, and were not therapeutic in adoptive immunotherapy at doses effective for day-7 and day-14 IVS-TDLN cells. In other experiments, IVS cells generated from different lymph node groups in animals bearing 10-day established s.c. tumors were examined and found to have unique profiles of cytokine release. In these studies, the ability of IVS cells to release specifically both cytokines as opposed to one was
Introduction
One of the difficulties in isolating or generating tumorreactive lymphoid cells for adoptive immunotherapy in man has been the availability of reliable in vitro assays that can predict in vivo therapeutic efficacy. Unlike animal studies, where therapeutic efficacy of immune lymphoid cells can be ascertained with in vivo models, characterization of the antitumor reactivity of human lymphoid cells has depended upon in vitro analyses. Many investigators have utilized in vitro tumor lysis as a method to identify potential therapeutic cells. However, there are many examples of non-lyric cells capable of mediating tumor regression in adoptive immunotherapy [8, 10, 16, 23] .
More recently, there have been reports suggesting that the elaboration of cytokines in tumor-bearing hosts plays a significant role in tumor regression. Barth et al. reported that the therapeutic efficacy of non-lyric TIL clones in a murine model was associated with the ability of these clones to secrete interferon y (IFNy) and tumor necrosis factor (TNF) in response to tumor in vitro [3] . The role of these cytokines as mediators of rumor regression in vivo was confirmed by the abrogation of the therapeutic effect of tumor-infiltrating lymphocytes (TIL) when neutralizing mAb was administered. In this context, TIL appeared to be a method to induce local elaboration of these cytokines at the sites of rumor, which resulted in tumor regression. In other studies, investigators have reported that the elaboration of various cytokines by genetically modified syngeneic tumor cells will result in reduced tumorigenicity and the induction of immunity to parental tumor antigens [12] .
These observations document a significant role of host immunity induced by certain cytokines elaborated in the local tumor environment. In a comparison of several different cytokines, Dranoff et al. identified granulocyte/ macrophage-colony-stimulating factor (GM-CSF) as one of the more potent immunoregulatory peptides, which when elaborated in the microenvironment of the tumor, elicited host immunity [7] .
We have previously reported that tumor-draining lymph nodes (TDLN) in animals bearing weakly immunogenic tumors harbor lymphoid cells with antitumor reactivity [5, 6] . These TDLN cells were precursors not capable of mediating tumor regression in adoptive immunotherapy, and required further in vitro activation in order to differentiate into functional effector cells. Hence, we have referred to TDLN cells as "pre-effector" lymphoid cells. One method to activate pre-effector lymphoid cells is to stimulate them with irradiated tumor cells in vitro in the presence of low concentrations of interleukin-2 (IL-2) [5] . In murine models, this in vitro sensitization (IVS) method generally required 9-10 days and resulted in a three-to five-fold expansion of tymphoblasts, which were predominantly CD8 + T cells. The adoptive transfer of these IVS-TDLN cells resulted in the complete regression of established macroscopic tumor associated with long-term survival in animal models [6] . Utilizing two immunologically distinct tumors induced chemically from the same murine host strain, we investigated the correlation between in vivo tumor reactivity and in vitro cytokine release mediated by IVS lymphoid cells. We found that the tumor-specific release of both GM-CSF and IFN 7 by IVS cells in culture was the best determinant of in vivo therapeutic efficacy.
IL-2
Human recombinant IL-2 was a gift from Chiron Therapeutics, Emeryville, Calif. It has a specific activity of 6 x 106 Cetus units/mg protein. One Cetus unit is equivalent to 6 international units (IU). In this study, amounts are expressed in international units in all of the experiments.
Tumor-draining lymph node B6 mice were inoculated s.c. with 1.5 • 106 MCA 207 or MCA 205 tumor cells in the lower flank. At specific intervals after tumor inoculation the adjacent tumor-draining inguinal lymph nodes were harvested, and single-cell suspensions prepared mechanically as described previously [23] . In other studies, axillary and mesenteric lymph nodes were similarly prepared for comparison with inguinal nodes. Axillary and mesenteric nodes represent further removed nodal sites compared with inguinal nodes in relation to lower-flank tumors. Single-cell suspensions were cultured by the IVS procedure.
IVS procedure
The procedure for generating IVS lymphoid cells has been previously described [6] . Briefly, 4 x 105 responding lymph node cells and 4 x 105 irradiated (60 Gy) MCA 207 or MCA 205 tumor stimulator cells were cultured in 2.0 ml complete medium (CM) containing 60 units/ml IL-2 in 24-well tissue-culture plates (Costar, Cambridge, Mass.). CM consisted of RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum, 0.01 mM non-essential amino acids, 1 ~tM sodium pyruvate, 2 mM fresh L-glutamine, 100 gg/ml streptomycin, 100 g/ml penicillin, 50 gg/ml gentamycin, and 0.5 gg/ml fungizone (all reagents from Gibco). The cultures were incubated at 37 ~ in 5% CO2 and were fed with 1.0 ml CM containing 60 IU/ml IL-2 on days 5 and 7. The IVS cells were routinely harvested on day 9 when they grew to a high density. These cells were washed three times before being resuspended in Hanks' balanced salt solution (HBSS) for adoptive immunotherapy or in CM for cytotoxicity and cytokine release.
Materials and methods

Mice
Female C57BL6 (B6) mice were purchased from The Jackson Laboratory (Bar Harbor, Me.) and maintained in a specific-pathogen-free environment. They were used at the age of 8 weeks or older. Principles of laboratory animal care (NIH publication 85-23, revised 1985) were followed, and animal protocols approved by the University of Michigan Laboratory of Animal Medicine.
Tumor
The MCA 207 and MCA 205 are 3-methylcholanthrene-induced fibrosarcomas, syngeneic to B6 mice. These tumors have been maintained in vivo by serial subcutaneous (s.c.) transplantation in B6 mice and were used within the seventh transplantation generation. They were kindly provided by Dr. James C. Yang (National Cancer Institute, NIH, Bethesda, Md.). These tumors have been previously characterized to be weakly immunogenic with distinct tumor-specific transplantation-rejection antigens [2] . Routinely, tumor cell suspensions were 
Generation of LAK cells
Lymphokine-activated killer (LAK) cells were generated by in vitro culture with high concentrations of IL-2. Briefly, l0 s normal B6 splenocytes were placed into 150-cm 2 (750 ml) flasks in 50 ml CM with 6000 IU/ml IL-2. The flasks were incubated at 37 ~ 5% CO2 for 72 h. The LAK cells were then harvested in sterile centrifugation tubes and washed three times in HBSS before resuspension in HBSS for i. v. injection or in CM for in vitro assays. Metastatic foci too numerous to count were assigned an arbitrary value of > 250. The significance of differences in numbers of metastatic nodules between experimental groups was determined using the nonparametric Wilcoxon rank-sum test. Two-sided P valanes below 0.05 were considered significant. Each group consisted of at least five mice, and no animal was excluded from the statistical evaluation. performed. For IFNu TNF~ and IL-4; standard curves starting at 1000 IU/ml, 50 ng/ml, and 1000 IU/ml respectively were established in a similar fashion. Experimental values were computed with the use of regression analysis. 
Measurement of in vitro cytokine release by IVS cells
Release of GM-CSF, IFN 7, TNF0~ and IL-4 by IVS lymphoid cells in response to tumor cell stimulation was assessed. IVS cells (1 x 106/ml) and irradiated tumor cells (5 x 105/ml) were co-cultured in 2.0-ml volumes in 24-well tissue-culture plates. Tumor cells were irradiated with 6000 cGy by a 137Cs source (500 cGy/min, Gamma Cell 1000 Irradiator, Atomic Energy of Canada). After 24 h, culture supernatants were collected and cytokine measurements assessed in duplicate using commercially available enzyme-linked immunosorbent assays (ELISA) (Pharmingen, San Diego, Calif.). For murine GM-CSF, a standard curve starting at 12.5 ng/ml with serial twofold dilutions was
Results
In vivo tumor specificity of IVS-TDLN cells did not correlate with in vitro cytolytic reactivity
The specificity of tumor regression mediated by IVS-TDLN was assessed by the adoptive immunotherapy of two immunologically distinct tumors in a criss-cross experiment. TDLN harvested 10 days after the s.c. inoculation of 1.5 x 106 MCA 205 or MCA 207 tumor cells were cultured by the IVS method. After IVS culture, 1.2 x 107 IVS cells were adoptively transferred to mice bearing 3-day puhnonary tumors along with the concomitant i.p. administration of 60 000 IU IL-2 twice daily for eight doses. As summarized in Table 1 , IL-2 administration alone did not result in tumor regression. However, the transfer of IVS-TDLN cells plus IL-2 mediated immunologically specific tumor regression. The phenotypic characteristic of TDLN cells were determined before and after IVS culture by fluorescenceactivated cell sorting. Fresh TDLN comprised approximately 30%-40% Thyl.2 + T cells with an approximately 2:1 ratio of CD4 : CD8-positive cells. After IVS culture, the cell population was at least 90% Thyl.2 + cells witlq~ virtually all the cells bearing CDS.
The in vitro cytolytic reactivity of the cells analyzed in adoptive immunotherapy (Table 1) was also evaluated using a 4-h 51Cr-release assay. Both IVS-TDLN populations mediated lytic reactivity against the tumor with which they were primed in vivo (Table 2 ). However, there was significant lysis of the unrelated tumor as well, albeit at a lower level. LAK cells generated from normal splenocytes by incubating in 6000 IU/ml IL-2 mediated non-specific lysis of both tumor targets as expected. The specificity of in vivo tumor regression mediated by IVS-TDLN was not Table 3 Tumor-specific cytokine release before and after IVS culture. TDLN cells were harvested from mice inoculated with MCA 205 or MCA 207 tumor cells as described in Table 1 . IVS cultures were established as described in Table 1 We next examined the kinetics of pre-effector cell development in TDLN. MCA 207 tumor cells were inoculated s.c. and TDLN harvested every few days for cryopreservation up to day 21 after tumor inoculation. Upon collecting all the TDLN from the different interval times, the cells were thawed, washed, and cultured by the IVS method. After IVS culture, these IVS-TDLN cells were assessed for therapeutic efficacy by adoptive transfer (1.2 x 107 cells/animal) into mice with established 3-day MCA 207 pulmonary metastases (Table 4) . TDLN harvested on days 0 and 4 had no therapeutic reactivity compared to control groups. IVS cells generated from TDLN harvested on days 7, 10 and 14 after tumor inoculation mediated significant regression of pulmonary metastases. By day 21, there was diminished pre-effector cell activity in the TDLN.
In kinetic studies, we also evaluated the tumor-specific cytokine release of the IVS-TDLN cells. After culture in IVS, TDLN cells were restimulated in vitro with irradiated MCA 207 or MCA 205 tumor and the supernatant was harvested 24 h later for cytokine (GM-CSF and IFNy) determinations (Fig. 1, 2 ). There were no significant amounts of GM-CSF or IFN 7 released by day-0 IVS-TDLN. Day-4 IVS-TDLN cells secreted high amounts of both cytokines non-specifically. Tumor-specific cytokine release was observed in TDLN harvested up to 14 days after tumor inoculation and diminished by day 21 to levels similar to those of day-0 TDLN (i. e., normal lymph nodes). These results suggested that a correlation existed between in vitro tumor-specific GM-CSF and IFNyrelease and the in Table 6 Minimal in vivo therapeutic efficacy of murine LAK in the therapy of MCA 207 pulmonary metastases. LAK cells were generated as described in Table 5 . The tumor reactivity of LAK cells was assessed in the adoptive immunotherapy of 3-day established MCA 207 pulmonary metastases as described in Table 1 No The non-specific release of cytokines demonstrated by day-4 TDLN was suggestive of a LAK-like phenomenon. Therefore, we proceeded to examine the cytokine-release profile and therapeutic efficacy of standard LAK cells in our models. The in vitro cytokine release mediated by LAK cells generated from normal splenocytes was evaluated. As demonstrated by in vitro cytotoxicity assays, LAK cells were found to lyse MCA 205 and MCA 207 in a nonspecific manner (Table 2 ). In both of two experiments, LAK cells were also found to release GM-CSF and IFNy nonspecifically when stimulated by irradiated MCA 205 and MCA 207 tumor in vitro ( Table 5 ). The therapeutic efficacy of LAK cells was examined in a dose-escalation fashion in the treatment of 3-day established MCA 207 pulmonary metastases (Table 6 ). At a dose of IVS-TDLN cells (i.e., 1.2 x 107) that significantly Table 5 Non-specific cytokine release of LAK cells. LAK cells were generated from splenocytes incubated in 6000 IU/ml IL-2 for 3 days. Cytokine release was measured in culture supernatants as described in Table 4 i  103  228  478  416  2  204  128  495  297 Distribution of pre-effector cells in different lymph nodes
The regional draining lymph node has been known to be a critical lymphoid organ during the immunological response to antigenic stimulation [19, 22] . We have previously demonstrated that the distribution of tumor-reactive preeffector cells can vary, depending upon the source of lymphoid ceils in the tumor-bearing host. We proceeded to investigate the correlation between tumor-specific cytokine release of IVS cells obtained from different lymph node sites of MCA 207 tumor-bearing hosts and their in vivo therapeutic efficacy. B6 mice were inoculated in the lower flank with MCA 207 tumor cells and 10 days later had inguinal, axillary and mesenteric lymph nodes removed for IVS culture. Normal splenocytes were used as control cells. After IVS culture, cells were assessed for in vitro cytokine release after tumor restimulation or in vivo tumor reactivity by the adoptive immunotherapy of pulmonary metastases as previously described. In order to quantify tumor-specific cytokine release, a specific release ratio (SRR) was calculated: SRR = total cytokine release against specific tumor tumor alone effectur cells alone total cytokine release against non specific tumor tumor alone effector cells alone As summarized in Table 7 , tumor regression was mediated by all three IVS-LN populations at the highest cell dose transferred (1.2 x 107) . However, dose titration revealed that the therapeutic potency of each cell popula- Table 7 Correlation between in vitro tumor-specific cytokine release and in vivo efficacy of different IVS-LN cells from MCA 207 tumorbearers. Mice were inoculated s.c. with MCA 207 tumor cells in the lower flank and underwent removal of lymph nodes (LN) 10 days later for IVS culture as described in Table 1 . Cytolytic activity (lyric units, LU) was determined by 20% lysis of l04 target cells in 106 effector cells. Mice were inoculated with MCA 207 tumor cells i.v. to establish pulmonary metastases; 3 days later, IVS-LN cells were adoptively transferred i.v. with the concomitant administration of IL-2 as described in Table 1 
Discussion
One of the major obstacles confronting investigators in the generation of tumor-reactive lymphocytes for adoptive immunotherapy is the unavailability of reliable in vitro assay methods to identify therapeutically functional effector cells. We and others have demonstrated that the use of standard 4-h chromium-release assays is not predictive of whether a particular cell population can mediate tumor regression in vivo [8, 10, 16, 23] . More recently, several reports have indicated that cytokine secretion by TIL appears to correlate with the in vivo tumor regression mediated by those cells. Barth et al. isolated several murine TIL clones from various methylcholanthrene(MCA)-induced tumors which were CD8 + and non-cytolytic [3] . He was able to demonstrate that the secretion of IFN 7 and TNFc~ upon restimulation of these TIL clones was associated with their antitumor reactivity in vivo. Moreover, the therapeutic efficacy of the cells was attenuated by neutralizing monoclonal antibodies to these cytokines. Goedegebuure et al. demonstrated that the release of IFN 7 and GM-CSF by TIL during activation and expansion with anti-CD3 and IL-2 appeared to correlate with their in vivo antitumor reactivity in the MCA 105 tumor model [9] . TIL isolated from different culture conditions were non-specifically lytic to various tumor targets in their study. They found that the elaboration of GM-CSF and IFN-7 by TIL during culture was associated with the magnitude of tumor regression manifested by the TIL after adoptive transfer. There have been few clinical studies of adoptive immunotherapy to determine whether one can extrapolate these observations to humans. In one of the largest clinical experiences with TIL therapy at the National Cancer Institute, Schwartzentruber et al. reported that the release of GM-CSF by TIL in response to autologous tumor appeared to be an important independent predictor of tumor response in melanoma patients [ 18] . We have further investigated the association of cytokine release by effector T cells and their therapeutic efficacy in vivo. Rather than utilizing TIL, we examined the in vitro reactivity of TDLN secondarily stimulated by tumor in an IVS culture method we have previously described [5, 6] . To evaluate tumor specificity we employed two immunologically distinct MCA-induced sarcomas that were derived in the same mouse strain. Tumor regression mediated by IVS-TDLN was exquisitely specific; however, the cytolytic reactivity was not. By contrast, the release of GM~CSF and IFN 7 by competent IVS-TDLN was highly tumorspecific.
We also observed that the ability to secrete GM-CSF or IFN7 in a non-specific manner was not as predictive as the specific release of these cytokines for the mediation of tumor regression in vivo. For example, LAK cells were found to elaborate high levels of GM-CSF and IFN 7 in a non-specific manner in vitro. Yet on a per cell basis, LAK cells were not as potent as IVS-TDLN cells that secreted cytokines in a tumor-specific fashion. Moreover, we found that day-4 IVS-TDLN secreted high amounts of GM-CSF and IFNy non-specifically and were therapeutically ineffective compared to day-7-14 IVS-TDLN, which released these cytokines in a tumor-specific manner. As a corollary, cells that did not secrete significant amounts of GM-CSF or IFN7 in response to in vitro tumor stimulation (i. e., normal splenocytes or day-21 TDLN) had no efficacy in adoptive immunotherapy.
The ability of effector cells to secrete both cytokines in a specific fashion appeared to be better than their release of a single cytokine. As noted in Table 7 , the tumor-specific release of IFN7 was demonstrated by IVS-cultured LN cells from inguinal, axillary and mesenteric node groups. At a relatively high dose of adoptively transferred cells (i. e., 1.2 • 107), tumor regression was mediated by all three cell populations. However, only inguinal lymph node cells that were derived from the closest nodal group draining the tumor inoculum demonstrated the specific release of both cytokines, and also had the most potent therapeutic effect in vivo on a per cell basis.
Both GM-CSF and IFNy have been found to be important cytokines in the host response to progressive tumors. Utilizing gene-transfer techniques several investigators have demonstrated that the elaboration of GM-CSF and IFNs' by genetically modified tumors will enhance T cell sensitization of the host. Using a poorly immunogenic tumor, Dranoff et al. reported that GM-CSF elaboration by the B16 melanoma was successful in establishing systemic immunity to wild-type tumor in a naive host [7] . Our laboratory, utilizing a subline of the B16 tumor, B16-BL6, demonstrated the ability to induce antitumor-reactive cells in lymph nodes draining a clone of the B16-BL6 engineered to secrete GM-CSE in contrast to wild-type tumor, which did not [1] . The antitumor reactivity of the lymph node cells was assessed in adoptive immunotherapy experiments. The role of GM-CSF in these models appears to be related to an increased influx of antigen-presenting cells to the local tumor environment as well as the draining lymph nodes. Other investigators have demonstrated the activation of dendritic cells by GM-CSF, which may also be important in antigen processing and presentation [4, 13, 17] . By similar mechanisms, the ability of adoptively transferred mature effector cells to elaborate GM-CSF in response to autologous tumor may be important in the recruitment of hot cells to respond at the site of progressive tumor.
The interferons have been postulated to have a variety of immunomodulatory effects important in tumor immunity. These include macrophage activation, naturall killer cell activation, and up-regulation of tumor antigens and MHC molecules [11] . Another novel role IFN 7 may serve is to induce tumor cells to become "non-professional" antigenpresenting cells. Restifo et al. observed that MCA 101, a poorly immunogenic murine sarcoma, developed the capability of processing exogenous antigen by genetically modifying a tumor line with IFN7 cDNA [14] . This was associated with up-regulation of tumor immunogenicity since TIL derived from IFNT-transduced MCA 101 were therapeutically effective compared to TIL generated from the wild-type tumor. The release of IFN 7 by adoptively transferred effector T cells may promote tumor regression via similar mechanisms.
We are currently evaluating the predictive effect of tumor-specific cytokine release with the functional in vivo antitumor activity of other effector populations. These include TDLN cells activated by anti-CD3 [23] , and bacterial superantigens [20] . These studies will also allow us to define the role of T cell subpopulations (CD4, CD8 and V~3 specific) in tumor reactivity in vitro and in vivo.
